3种方案治疗幽门螺杆菌感染的成本效果分析

目的:对幽门螺杆菌(Hp)感染的3种药物治疗方案进行药物经济学评价.方法:A组用兰索拉唑30mg 呋喃唑酮100mg 克拉霉素250mg,bid×7d 兰索拉唑30mg,qd×14 d;B组用雷贝拉唑10 mg 呋喃唑酮100mg 克拉霉素250 mg,bid×7 d 雷贝拉唑10 mg,qd×14 d;C组用奥美拉唑20 mg 呋喃唑酮100mg 克拉霉素250mg,bid×7 d 奥美拉唑20 mg,qd×14 d.用成本效果分析法对3种方案进行分析.结果:A,B,C 3种方案的成本效果比(C/E)分别为18.60,20.04,16.30.结论:方案C是3种方案中最经济、合理的方案.

Pharmacoeconomical analysis of three therapeutic regimens for Helicobacter pylori infection

Objective:To evaluate the pharmacoeconomical outcome of three therapeutic regimens for Helicobacter pylori infection.Methods:Three therapeutic regimens for Helicobacter pylori infection were compared by a cost-effectiveness analysis.These regimens were composed of lansoprazole 30 mg+furazolidone 100 mg+clarithromycin 250 mg,bid,for 7 days and then lansoprazole 30 mg,qd,for 14 days(scheme A);rabeprazole 10 mg+furazolidone 100 mg+clarithromycin 250 mg,bid,for 7 days and then rabeprazole 10 mg,qd,for 14 days (scheme B);and omeprazole 20 mg+furazolidone 100 mg+clarithromycin 250 mg,bid,for 7 days and then omeprazole 20 mg,qd,for 14 days(scheme C).Results:The cost effectiveness ratio of three regimens was 18.60,20.04 and 16.30,respectively.Conclusion:The scheme 3 was considered the best regimen in the viewpoint of pharmacoeconomics.